Search by Drug Name or NDC
NDC 49702-0242-13 Juluca 50; 25 mg/1; mg/1 Details
Juluca 50; 25 mg/1; mg/1
Juluca is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by ViiV Healthcare Company. The primary component is DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE.
MedlinePlus Drug Summary
Dolutegravir is used with other medications to treat human immunodeficiency virus (HIV) infection in adults and children 4 weeks of age and older who weigh at least 6.6 lbs (3 kg). It is also used in combination with rilpivirine (Edurant) to treat HIV in certain adults to replace their current HIV medication(s) that has been taken for at least 6 months. Dolutegravir is in a class of medications called HIV integrase inhibitors. It works by decreasing the amount of HIV in your blood and increasing the number of immune cells that help fight infections in your body. Although dolutegravir does not cure HIV, using it along with other medications may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of transmitting (spreading) the HIV virus to other people.
Related Packages: 49702-0242-13Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Dolutegravir
Rilpivirine is used along with other medications to treat human immunodeficiency virus type 1 (HIV-1) in certain adults and children 12 years of age and older who weigh at least 77 lb (35 kg) and have not received antiretroviral treatment in the past. It is also used along with cabotegravir (Vocabria) as a short-term treatment of HIV-1 infection in certain adults. Rilpivirine is in a class of medications called non-nucleoside reverse transcriptase inhibitors (NNRTIs). It works by decreasing the amount of HIV in the blood. Although rilpivirine does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of transmitting (spreading) the HIV virus to other people.
Related Packages: 49702-0242-13Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Rilpivirine
Product Information
| NDC | 49702-0242 |
|---|---|
| Product ID | 49702-242_4c047819-54a8-4773-b377-0053f987f6bf |
| Associated GPIs | 12109902280320 |
| GCN Sequence Number | 077948 |
| GCN Sequence Number Description | dolutegravir/rilpivirine TABLET 50 MG-25MG ORAL |
| HIC3 | W0I |
| HIC3 Description | ANTIRETROVIRAL-INTEGRASE INHIBITOR AND NNRTI COMB. |
| GCN | 44119 |
| HICL Sequence Number | 044647 |
| HICL Sequence Number Description | DOLUTEGRAVIR SODIUM/RILPIVIRINE HCL |
| Brand/Generic | Brand |
| Proprietary Name | Juluca |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | dolutegravir sodium and rilpivirine hydrochloride |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 50; 25 |
| Active Ingredient Units | mg/1; mg/1 |
| Substance Name | DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE |
| Labeler Name | ViiV Healthcare Company |
| Pharmaceutical Class | HIV Integrase Inhibitors [MoA], Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC], Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA210192 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 49702-0242-13 (49702024213)
| NDC Package Code | 49702-242-13 |
|---|---|
| Billing NDC | 49702024213 |
| Package | 30 TABLET, FILM COATED in 1 BOTTLE (49702-242-13) |
| Marketing Start Date | 2017-11-21 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 113.29 |
| Pricing Unit | EA |
| Effective Date | 2024-01-01 |
| NDC Description | JULUCA 50-25 MG TABLET |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 4 |
| Classification for Rate Setting | B |
| As of Date | 2024-02-21 |